Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.04 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.27 +11.9% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.51 +1.2% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0% S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.04 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.27 +11.9% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.51 +1.2% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0%
Regulatory Neutral

KDA GROUP ANNOUNCES RESULTS OF SHAREHOLDERS' ANNUAL GENERAL MEETING AND THE SETTLEMENT OF JUDICIAL CLAIMS

Governance Cleanup Amidst Valuation Trough

By The Northwire Desk — AI Analysis May 05, 2026 · 13:30 KDA · 0.1 KDA Group Inc.
Executive Summary
  • KDA Group held its Annual General Meeting (AGM) on April 29, 2026, with results announced May 5, 2026.
  • Shareholders re-elected five directors including Claude Auger and Dr. Jacques Turgeon with over 99% approval.
  • Jean-Marc Léveillé appointed as Chairman of the Board, President, and Chief Executive Officer (CEO).
  • Michael W. Kinley appointed as Chief Financial Officer (CFO).
  • Forvis Mazars, LLP appointed as auditor for the 2026 financial year.
  • Two legal disputes with former executives were settled:
    • Dispute 1: Former executive claimed $808,191 plus shares; resolved via $190,000 cash payment and issuance of 250,000 common shares at $0.10/share value.
    • Dispute 2: Former executive claimed $760,000 under terminated contract; resolved via $215,000 cash payment.
  • Total disclosed cash settlement cost is approximately $430,000 plus share issuance dilution.
Material Impact
  • Governance Stability: The AGM results confirm board continuity and appoint new leadership, removing uncertainty regarding management succession. However, the replacement of Marc Lemieux (who was Chairman/CEO in late 2025 news) with Jean-Marc Léveillé suggests a strategic pivot or internal restructuring that may unsettle investors accustomed to previous leadership.
  • Legal Overhang Removal: Settling disputes with former executives removes potential liabilities and litigation risks, which is positive for long-term balance sheet health but comes at an immediate cash cost.
  • Dilution Impact: The issuance of 250,000 shares for legal settlement adds to the float. Combined with the 35 million shares issued in December 2025 for the GTK acquisition (News ID 126044), significant dilution has occurred over the past year.
  • Cash Burn: The $430,000 cash outflow is material for a company trading at $0.10/share with no disclosed revenue milestones in this release. It indicates liquidity usage rather than capital raising.
  • Market Context: The news arrives after a 70% decline from the July 2025 high ($0.39) to current levels ($0.10). The market has likely already priced in governance risks and dilution, making this announcement incremental rather than transformative.
KDA · Price
Company Overview
  • Company: KDA Group Inc., a technology-focused healthcare company listed on the TSX Venture Exchange.
  • Flagship Project: Medherize, a SaaS platform for therapeutic monitoring of oral anticancer therapies (OAM).
  • Development Status:
    • Deployed at CHU de Québec and Hôpital du Saint-Sacrement (approx. 200 monitored patients).
    • Expanded to community pharmacies (Horizon Santé, Jean Coutu) in Quebec as of December 2025.
    • US subsidiary formed in November 2025 with commercialization planned for 2026.
  • Strategic Focus: Commercializing Medherize across Canada and internationally, targeting the $243 billion specialty drug market.
Read the original news release →

More from KDA Group Inc.

Jun 18, 2026 · 13:15

Clinical validation of Medherize confirms value prop, but tiny revenue and depleted cash demand urgent capital raise.

Other May 29, 2026 · 18:00

KDA Group Settles Debt with Equity Amidst Share Price Collapse

Financings Dec 24, 2025 · 11:00

UPDATE OF THE TRANSACTION ANNOUNCED ON NOVEMBER 25, 2025, FOR THE ACQUISITION OF THE MINORITY INTEREST IN THE SUBSIDIARY GROUPE TECHNOLOGIQUE KDA INC.

M&A / Property Dec 03, 2025 · 10:30

KDA GROUP ANNOUNCES PARTNERSHIP AGREEMENT WITH CHU DE QUEBEC-UNIVERSITE LAVAL FOR THE DEPLOYMENT OF MEDHERIZE

M&A / Property Dec 01, 2025 · 13:45

KDA GROUP DEPLOYS MEDHERIZE ACROSS COMMUNITY PHARMACIES: A MAJOR STEP FORWARD IN THE MANAGEMENT OF ORAL ANTICANCER THERAPIES

Production / Operations Nov 25, 2025 · 15:00

KDA GROUP ANNOUNCES AGREEMENT TO ACQUIRE MINORITY INTEREST IN ITS SUBSIDIARY GROUPE TECHNOLOGIQUE KDA INC.

M&A / Property